Page 97 - CIBEROBN2016-ENG

• Study of the epigenetic profiles according to their relationships with obesity-diabetes and cancer- obesity. We are studying the epigenetic modifications of the genes implicated in the molecular mechanisms of expression repression and of the transcription factors implicated in obesity and insulin resistance, associated to the development of tumors in humans.
• PREDIMED+ Study. In this line, we are focused on the study of a Mediterranean diet intervention with olive oil and nuts (pistachios and almonds), in order to prevent the cardiovascular disease in overweight/obese metabolic syndrome patients.
Most relevant scientific articles
• Moreno-Indias I., Sánchez-Alcoholado L., Sánchez-Garrido M.A., Martín-Nunez G.M., Pérez-Jiménez F., Tena-Sempere M. et al. Neonatal androgen exposure causes persistent gut microbiota dysbiosis related to metabolic disease in adult female rats. Endocrinology. 2016;157(12):4888-4898.
• Rosenstock J., Guerci B., Hanefeld M., Gentile S., Aronson R., Tinahones F.J. et al. Prandial options to advance basal insulin glargine therapy: Testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: The GetGoal Duo-2 Trial. Diabetes Care. 2016;39(8):1318-1328.
• El Bekay R., Coin-Araguez L., Fernández-GarcÍa D., Oliva-Olivera W., Bernal-López R., Clemente-Postigo M. et al. Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. British Journal of Pharmacology. 2016;173(11):1820-1834.
• Moreno-Indias I., Oliva-Olivera W., Omiste A., Castellano-Castillo D., Lhamyani S., Camargo A. et al. Adipose tissue infiltration in normal-weight subjects and its impact on metabolic function. Translational Research. 2016;172:6-17.
• Lagarrigue S., López-Mejia I.C., Denechaud P.-D., Escote X., Castillo-Armengol J., Jiménez V. et al. CDK4 is an essential insulin effector in adipocytes. Journal of Clinical Investigation. 2016;126(1):335-348.
Hightlights
PATENTS: As result of the microbiota and metabolic disease research lines, two patents have been generated with the aim of the clinical use of probiotics. Currently, they are in internationalization phase and there are some companies interested in them. The collaborative research line with Dr. Casanueva has also generated a new patent in order to protect the finding of new biomarkers for colon cancer diagnosis and prognostic in obese patients.
TRANSLATION: The node participates in a number of clinical trials and it has been published four articles
in high-impact journals in 2016 that has been authored by some researchers of our node. The results of some of these clinical trials will change the clinical practice in patients with obesity and diabetes.
COLLABORATIONS AND SYNERGY: Our node organizes every year networking meetings with other groups of the CIBERDEM and guest European researchers. The fourth meeting has taken place in 2017. As result of these interactions the number of collaborative works with groups form the CIBERdem has been increased, and among them it worth mentioning the article published in the Journal Clinical Investigation.
METAGENOMIC PLATFORM START-UP: This platform has been launched in 2016. In the last three months, more than 400 analyses have been done with samples from projects of this node, interCIBER and intraCIBEROBN.
NODE CRITICAL MASS INCORPORATION IN 2016: Two contracts from the Juan de la Cierva program and one contract from Sara Borrel program has been obtained in 2016. In addition, a new Miguel Servet contract has been incorporated in the node.
OBN
Research groups 97